Abstract
8038 Background: EGFR-mutant “oncogene-addicted” cancers are a distinct form of NSCLC that can be targeted with erlotinib (Paz-Ares et al. ASCO 2006). Methods: From April 2005 to December 2007, tum...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
